Cognition Therapeutics (NASDAQ: CGTX) has extended the duration of the expanded access program (EAP) for dementia with Lewy bodies (DLB) from the original 12 months to include several more months of treatment.
According to Cognition, the EAP is part of the company’s larger clinical development program in DLB, which included the Phase 2 SHIMMER study and planned clinical programs.
In a statement, Anthony O. Caggiano, MD, PhD, CMO of Cognition, commented, “The EAP has been running since June 2025 and is expected to provide us with additional long-term safety data. We’ve received favorable feedback during the program from participants and their care partners about their experience in this program. We implemented a strategy that reduces the amount of travel for patients to clinical sites by empowering their local physicians to conduct routine health monitoring and allowing local laboratory testing. Doctors and patients appreciate these operational aspects of the program.”
